Target intelligence / Profile preview

Inwardly rectifying potassium channel 4.1 (Kir4.1) (Kir4.1)

Target
Kir4.1
Molecular classification
Ion channel, Potassium channel, Inwardly rectifying potassium channel
01

Overview

Inwardly rectifying potassium channel 4.1 (Kir4.1), encoded by the KCNJ10 gene, is a member of the inwardly rectifying potassium channel family. It is predominantly expressed in glial cells of the central nervous system (astrocytes and oligodendrocytes), the inner ear (stria vascularis), and the basolateral membrane of the kidney's distal convoluted tubules. In the brain, Kir4.1 plays a critical role in spatial potassium buffering, clearing excess extracellular potassium ions released during neuronal activity, and maintaining glutamate homeostasis. In the inner ear, it is essential for generating the endocochlear potential required for hearing, while in the kidney, it supports sodium and magnesium reabsorption. Loss-of-function mutations in KCNJ10 cause EAST (Epilepsy, Ataxia, Sensorineural deafness, and Tubulopathy) or SeSAME syndrome, highlighting its physiological importance. Conversely, dysregulation of Kir4.1 is implicated in major depressive disorder, chronic pain, Huntington's disease, and epilepsy. Pharmacologically, Kir4.1 is inhibited by several tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and selective serotonin reuptake inhibitors (e.g., fluoxetine), which may contribute to their therapeutic effects by modulating glial-neuronal communication and increasing brain-derived neurotrophic factor (BDNF) expression. Developing selective modulators of Kir4.1 represents a promising therapeutic strategy for neurological and psychiatric disorders, though targeting this channel carries significant safety risks, including seizures, hearing impairment, and renal electrolyte imbalances.

Other names
KCNJ10Potassium inwardly-rectifying channel subfamily J member 10ATP-sensitive inward rectifier potassium channel 10Glial ATP-dependent inwardly rectifying potassium channel KIR4.1Inward rectifier K(+) channel Kir1.2BIRK-10KIR1.2SESAME
02

Mechanism of action

Inwardly rectifying potassium channel blocker

03

Biological functions

Potassium homeostasisGlial potassium bufferingRegulation of membrane potentialGlutamate clearanceEndocochlear potential generationElectrolyte transport
04

Disease associations

EpilepsyEAST syndromeSeSAME syndromeDepressionChronic painHuntington's diseaseMultiple sclerosisAutism spectrum disorder
05

Safety considerations

Seizure susceptibilityHearing lossRenal tubulopathyElectrolyte imbalanceAtaxiaBlood-brain barrier disruption
06

Interacting drugs

13 more in the full profile.

07

Biomarkers

KIR4.1 autoantibodiesKCNJ10 genetic variantsBrain-derived neurotrophic factor (BDNF)

Beyond the preview

Go deeper on Inwardly rectifying potassium channel 4.1 (Kir4.1) (Kir4.1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inwardly rectifying potassium channel 4.1 (Kir4.1) (Kir4.1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call